Richard Law: Right. Okay. A follow-up question to that is that, is there any performance requirement in the licensing agreement that you have with the broad, that you have to continuously perform product development with the Cas9 technology?
Gilmore O’Neill: I’m not going to go into details, but obviously, like any agreement there are conditions or requirements to execute. And ours are a mixture around both on our business development and execution.
Richard Law: Okay. Great. Thank you.
Operator: Our next question is from Madhu Kumar with Goldman Sachs. Please proceed.
Unidentified Analyst: Hey, thanks for taking our question. This is (Ph) on for Madhu, two quick ones. What venue should we expect the mid 2023, 301 update, it is like medical meeting or company release. And then how do you think about the regulatory path in in-vivo CRISPR in the U.S. given the headwinds we have seen by some of your peers? Thank you.
Gilmore O’Neill: Baisong, do you want to take the first question? I will take the second.
Baisong Mei: Sure. Yes. So we plan to release the RUBY data middle of the year, as well as end of the year. The specific venue we have not decided, we will share in the later time.
Gilmore O’Neill: Thanks very much, Baisong. And then with regard to the regulatory path for in-vivo CRISPR, what I would actually say, I’m not going to comment on others experiences, the regulators. I will say that one of the things that drew me to Editas was the substantial investment and depth of expertise built in both its research analytics, as well as the CMC analytics from the point of view of certainly managing risk, et cetera. And so I actually feel, you know, very good about where we are, from that point of view. And obviously as we move forward, we will engage with regulators, including the FDA to determine the path to our first-in-human.
Unidentified Analyst: Thank you.
Gilmore O’Neill: Thanks very much.
Operator: Our next question is from Matthew Harrison with Morgan Stanley. Please proceed.
Unidentified Analyst: Thanks for taking our questions. This is (Ph) on for Matthew. We have two questions. One is about the SCD filing package. You mentioned a few times that you need to talk to the regulators about that, but do you think it is possible that you could be in a position to file in 2024? And then the second question is about the BMS collaboration. Is it possible to see an update in 2023, and how should we think about any of those programs progressing into the clinic? Thank you.
Gilmore O’Neill: Thanks very much. I think – let me take both questions regarding the filing package. Certainly I admire your aggressive posture there. I think any question around timing of filings and what is required is really a matter of negotiation with the agencies and that is only something that we will know as we progress in negotiations with them. With regard to the BMS collaboration we are happy with the collaboration. BMS has actually received a lot of nice data from us and actually nominated a number of targets. We hope that that will continue to progress. But with regard to the specifics of advancing towards the clinic that really is driven by, and the announcements are driven by BMS. As I say, we are very excited by the collaboration and delighted to see the progress.
Unidentified Analyst: Thank you very much.
Operator: Our final question is from Liisa Bayko with Evercore ISI. Please proceed.
Liisa Bayko: Hi, all my questions has been answered, but thanks for taking me in.
Gilmore O’Neill: Thanks Liisa
Operator: Thank you. This will conclude today’s conference. You may disconnect your lines at this time and thank you for your participation.
